We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human||Dog (Canine)||Mouse (Murine)|
|Western Blotting (WB)||657 Antibodies||19 Antibodies||193 Antibodies|
|Radioimmunoassay (RIA)||2 Antibodies|
|Proximity Ligation Assay (PLA)||3 Antibodies|
|Luminex Assay (LMNX)||21 Antibodies|
|Intracellular Flow Cytometry (ICFC)||3 Antibodies|
|Immunostaining (ISt)||1 Antibodies|
|Immunoprecipitation (IP)||171 Antibodies||24 Antibodies||4 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||226 Antibodies||53 Antibodies||7 Antibodies|
|Immunohistochemistry (IHC)||331 Antibodies||92 Antibodies||7 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||100 Antibodies||3 Antibodies|
|Antigen||V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian) (ERBB2) Antibodies|
|Epitope||AA 860-880 Alternatives|
|Reactivity||Dog (Canine), Human, Mouse (Murine) Alternatives|
|Conjugate||This HER2 antibody is un-conjugated Alternatives|
Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-HER2 AntibodyTarget Details HER2 Application Details Handling Images
|Specificity||This antibody specifically recognizes the intracellular domain of erbB2.|
|Characteristics||Synonyms: HER-2, NEU, p185erbB2, NGL, c-erbB-2, MNL19, Receptor tyrosine-protein kinase erbB-2,NEU proto-oncogene, Tyrosine kinase-type cell surface receptor HER2|
|Purification||Subsequent Ultrafiltration and Size Exclusion Chromatography|
|Components||incl. positive Control|
|Immunogen||Synthetic petide conjugated to KLH.|
Target Details HER2Product Details anti-HER2 Antibody Application Details Handling Images back to top
|Alternative Name||CD340 / ERBB2 / HER2 (ERBB2 Antibody Abstract)|
|Background||ErbB2 is a member of the EGFR/erbB-receptor tyrosine kinase family. Dysregulation of erbB2 and/or activation of downstream signaling pathways has been implicated in many human cancers. ErbB2 is activated upon ligand dependent heterodimerization with EGFR or erbB4. ErbB2 homodimers are not favored due to the lack of an erbB2 specific extracellular ligand. Heterodimerization with EGFR or erbB4 leads to activation of the intrinsic tyrosine kinase activity of EGFR or erbB4 resulting in phosphorylation of multiple tyrosine residues within the erbB2 intracellular domain: Tyr 1023, Tyr 1112, Tyr 1139, Tyr 1196, Tyr 1222, and Tyr 1248.Transphosphorylation via src family kinases leads to phosphorylation of Tyr 877, via PKC of Thr 686, via CamKinase2 of Ser 1113. Phosphorylation of Thr 686 and Ser 1113 interferes with erbB2 endocytosis and degradation.Synonyms: HER-2, MNL19, NEU, NEU proto-oncogene, NGL, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, c-erbB-2, p185erbB2|
|Molecular Weight||185 kDa|
|Pathways||RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway|
Application DetailsProduct Details anti-HER2 Antibody Target Details HER2 Handling Images back to top
Western Blot: 0.5 μg/mL for HRPO/ECL detection. Recommended blocking buffer: Casein/Tween 20 based blocking and blot incubationbuffer.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Restrictions||For Research Use only|
HandlingProduct Details anti-HER2 Antibody Target Details HER2 Application Details Images back to top
|Reconstitution||Restore with 1 mL H2O (15 min, RT).|
|Buffer||1 mLPBS containing 0.09 % Sodium Azide, PEG and Sucrose|
|Precaution of Use||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage||-20 °C/-80 °C|
Store lyophilized (preferably in a desiccator) at -20 °C and reconstituted (aliquote andfreeze in liquid nitrogen) at -80 °C. Avoid repeated freezing and thawing. Thaw aliquots at 37 °C. Thawed aliquots may be stored at 4 °C up to 3 months.
Shelf life: one year from despatch.
|Expiry Date||12 months|
ImagesProduct Details anti-HER2 Antibody Target Details HER2 Application Details Handling back to top